This paper is part 5 in Blue Matter’s series on the “rare disease ecosystem.” It outlines key questions and considerations for biopharmaceutical companies as they develop pricing, access, and reimbursement strategies for rare disease therapeutics.
Other installments in the series can be accessed via these links:
Part 2 – Optimizing Clinical Trial Design
Part 3 – Continuous Evidence Generation
Part 4 – Clinical Trial Implementation